104579-03-5

Basic information

• Product Name: 5'-O-(4,4'-DIMETHOXYTRITYL)-N4-BENZOYL-5-METHYL-2'-DEOXYCYTIDINE
• Synonyms: 5'-O-(4,4'-DIMETHOXYTRITYL)-N4-BENZOYL-5-METHYL-2'-DEOXYCYTIDINE;DMT-NBZ-5-METHYL DC;Cytidine, N-benzoyl-5'-O-[bis(4-Methoxyphenyl)phenylMethyl]-2'-deoxy-5-Methyl-;77: PN: US20040005707 PAGE: 17 claimed DNA;N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-5-methylcytidine;WO03106645 PAGE: 62 claimed DNA
• CAS NO: 104579-03-5
• Molecular Formula: C₃₈H₃₇N₃O₇
• Molecular Weight: 647.72
• Mol File: 104579-03-5.mol

Chemical Properties

• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: Store at 0°C
• PKA: 8.69±0.40(Predicted)
• CAS DataBase Reference: 5'-O-(4,4'-DIMETHOXYTRITYL)-N4-BENZOYL-5-METHYL-2'-DEOXYCYTIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-(4,4'-DIMETHOXYTRITYL)-N4-BENZOYL-5-METHYL-2'-DEOXYCYTIDINE(104579-03-5)
• EPA Substance Registry System: 5'-O-(4,4'-DIMETHOXYTRITYL)-N4-BENZOYL-5-METHYL-2'-DEOXYCYTIDINE(104579-03-5)

Safety Data

• Hazardous Substances Data: 104579-03-5(Hazardous Substances Data)

Usage

Uses

5''-O-(4,4''-Dimethoxytrityl)-n4-benzoyl-5-methyl-2''-deoxycytidine

Upstream product

• 126144-60-3 3'-O-trimethylsilyl-5'-O-dimethoxytrityl-thymidine 
• 838-07-3 5-methyldeoxycytidine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 93-97-0 benzoic acid anhydride 
• 176755-83-2 5'-O-(4,4'-dimethoxytrityl)-2'-deoxy-5-methylcytidine 
• 76512-82-8 5'-O-(4,4'-dimethoxytrityl)deoxycytidine 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 98-88-4 benzoyl chloride 
• 5241-10-1 5-methyl-2'-deoxycytidine hydrochloride 
• 93134-37-3 5'-O-(4,4'-dimethoxytrityl)-3'-O-levulinoyl-2'-deoxythymidine 
• 50-89-5 thymidine 
• 40615-39-2 5'-O-(4-4'-dimethoxytrityl)thymidine 
• 847699-97-2 benzoic acid 5-(4-benzoylamino-5-methyl-2-oxo-2H-pyrimidin-1-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-yl ester 
• 104579-02-4 4-N-benzoyl-5-methyl-2'-deoxycytidine 

Downstream Products

• 166758-14-1 N⁴-Benzoyl-3'-O-(tert-butyldiphenylsilyl)-5-methyl-2'-deoxycytidine 
• 105931-57-5 5-methyl dC amidite 
• 146961-99-1 C₅₇H₅₇N₅O₁₃S 
• 149510-50-9 C₄₉H₅₁N₅O₁₁S 
• 146961-98-0 Phenoxy-acetic acid (2R,3S,5R)-5-(4-benzoylamino-5-methyl-2-oxo-2H-pyrimidin-1-yl)-2-chloromethoxymethyl-tetrahydro-furan-3-yl ester 
• 146961-97-9 N⁴-benzoyl-5-methyl-2'-deoxy-3'-O-(phenoxyacetyl)cytidine 
• 104579-04-6 d-<(MeO)2Tr>bzm⁵Cp^. 
• 1053703-48-2 Phenoxy-acetic acid (2R,3S,5R)-5-(4-benzoylamino-5-methyl-2-oxo-2H-pyrimidin-1-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-yl ester 
• 106022-55-3 Diisopropyl-phosphoramidous acid (2R,3S,5R)-5-(4-benzoylamino-5-methyl-2-oxo-2H-pyrimidin-1-yl)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-tetrahydro-furan-3-yl ester methyl ester 

Relevant articles and documents

Novel anthraquinone conjugate of 2,2-bis(hydroxymethyl)propionic acid incorporated to a TFO with phosphodiester linkage facilitates triplex formation with dsDNA bearing a pyrimidine-gapped polypurine sequence

An anthraquinone derivative conjugated with 2,2-bis(hydroxymethyl) propionic acid as a novel non-nucleosidic component was synthesized and successfully incorporated into an internal region of 14-mer triplex-forming oligonucleotide (TFO) via the phosphoramidite method. The resulted novel TFO exhibits remarkable enhancement effect on the thermal stability of a DNA triplex upon binding to a pyrimidine-gap containing polyprurine sequence.

Synthesis of 2-deoxy ribose related disaccharide nucleoside and its phosphoramidite

Synthesis of impurity reference compound of anti-tumor drug ISIS 183750 was achieved. In this process, a general method for synthesis of 2-deoxy ribosyl disaccharide nucleosides was established for the first time.

Efficient large-scale synthesis of 5′-O-dimethoxytrityl-N 4-benzoyl-5-methyl-2′-deoxycytidine

An efficient process to synthesize 5′- O -dimethoxytrityl-N 4 -benzoyl-5-methyl-2 ′-deoxycytidine in high yield and quality is described. Final benzoylation was improved by developing a method to selectively hydrolyze benzoyl ester impurities. This inexpensive approach was scaled up to multi-kilogram quantities for routine use in oligonucleotide therapeutics. Copyright Taylor & Francis Group, LLC.

Metallic salt of N4-acylcytidine derivatives, and a method for producing N4-acylcytidine derivatives using the same

The present invention provides a method for producing a high purity N4-acylcytidine derivative. More specially, the invention provides a compound represented by the formula (1): wherein R1 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms, a perfluoroalkyl group having 1 to 4 carbon atoms, or a halogen atom; R2 is a hydrogen atom, an alkoxyl group having 1 to 4 carbon atoms, an alkoxyl group having 1 to 4 carbon atoms with a substituent, or a halogen atom; R3 represents a methyl group or a phenyl group; and M represents a positive ion of an alkali metal or an alkaline earth metal, and a compound represented by the formula (2): wherein R1, R2, and R3 are as defined above, produced by using the compound represented by the formula (1).

Modulation of DC-SIGN expression

Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.

Oligonucleotides having modified nucleoside units

Disclosed are oligonucleotide that include one or more modified nucleoside units. The oligonucleotides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

Oligonucleotides having modified nucleoside units

Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

Antisense modulation of PPP3CB expression

Antisense compounds, compositions and methods are provided for modulating the expression of PPP3CB. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP3CB. Methods of using these compounds for modulation of PPP3CB expression and for treatment of diseases associated with expression of PPP3CB are provided.